The structure of a human antibody bound to the Zika virus may help in the development of antiviral medications.
All articles by John Schieszer, MA
Recent research found that end-of-rotation transition in care was linked to significantly higher in-hospital mortality.
The incidence of hepatocellular carcinoma after sustained virological response has not increased with the widespread use of all oral direct antivirals regimens as suggested in previous studies, according to a new study.
Prevalence of active HIV-HCV coinfection may decrease to 1.1% in France over the next decade.
Researchers quantify inducible virus in long-term suppressed patients that was missed by the gold standard assay that measures the latent reservoir.
Study looking at the use of 2 frequently used protease inhibitors (atazanavir and darunavir) is suggesting that cumulative use of darunavir may be independently associated with a small but gradually increasing cardiovascular disease (CVD) risk.
New study suggests that the vaginal microbiome may modify tenofovir delivery.
Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.
Viral loads can fluctuate over time depending on patients’ access and response to HIV treatment, their medication adherence behavior, and care status.
The once-daily dosing doravirine appears to have similar efficacy and to be non-inferior to once-daily ritonavir-boosted darunavir (DRV+r) on a background of 2 NRTIs in HIV-1 treatment-naïve adults.
The current sexual prevention guidelines recommend that men use condoms or abstain from sex for 6 months after Zika virus exposure. Now there are strong data to support these guidelines.
Vaccines against HIV/AIDS enter a new era.